Home - Quirem Medical

You are unique, and your treatment should be too.

To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.

LifeHAck

Introducing Q-Suite™

Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.

LEARN MORE

Events

Meet us in Barcelona at CIRSE 2019

The Quirem team will attend CIRSE in Barcelona from September 7-11 2019.

Visit the CIRSE website

SIRT in three steps

Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:

1. SELECT

Select only those patients that are likely to benefit from SIRT. Use QuiremScout^®, a safe dose of holmium microspheres, to evaluate the biodistribution of particles prior to therapy in your patients.

2. TREAT

Treat with QuiremSpheres^®, the next-generation microspheres, indicated for treatment of unresectable liver tumors. Click here to learn what value QuiremSpheres® can bring to your clinic.

3. VERIFY

Use our software package Q-Suite^TM to determine SIRT succes right after the procedure, by evaluating the absorbed dose in the lesions and normal liver tissue

News and events

First clinical case using the McMaster Nuclear Reactor

McMaster University and Quirem Medical announce the first clinical case using the McMaster Nuclear Reactor Deventer (The Netherlands), Hamilton (Canada), 6th of June 2019 McMaster University and Quirem Medical announce the first clinical case using

June 6, 2019

The first QuiremScout cases successfully performed

The first QuiremScout® cases have been successfully performed by clinical teams in Dresden and Pisa last week. We congratulate the clinical teams, and everyone involved! QuiremScout® is the first and only CE-marked SIRT work-up product

February 13, 2019

QuiremScout receives CE mark

Terumo Europe today announced that QuiremScout® has received CE mark, making it available as the first and only CE marked product indicated for SIRT work up, for clinical centers throughout Europe. QuiremScout® is designed to

January 7, 2019

What our customers say

“QuiremSpheres^® gives us the confidence we need to start individualizing treatments.”

"QuiremScout^® enables us to evaluate the safety and efficacy profile of SIRT, prior to the therapeutic procedure. We can now select and treat only those patients that are likely to benefit from SIRT."

“The short halftime of holmium-166 in QuiremSpheres^® results in a high initial dose rate. Therefore, we expect to see an improved radiobiological effect.”

Zutphenseweg 55

7418AH Deventer

The Netherlands

Telephone: +31 85 0404170

E-mail: info@quirem.com